192 related articles for article (PubMed ID: 36062548)
21. Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R; de la Fuente MI
Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
[TBL] [Abstract][Full Text] [Related]
22. FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Zhou K; Jiang T; Liu Y; Zhao Z; Huang L; Li G
BMC Neurol; 2021 Nov; 21(1):438. PubMed ID: 34753441
[TBL] [Abstract][Full Text] [Related]
23. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
24. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
[TBL] [Abstract][Full Text] [Related]
25. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
26. Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.
Ramkissoon LA; Britt N; Guevara A; Whitt E; Severson E; Sathyan P; Gay L; Elvin J; Ross JS; Brown C; Stogner-Underwood K; Mott R; Kram D; Strowd R; Lesser GJ; Ramkissoon SH
Curr Treat Options Oncol; 2018 Jun; 19(8):41. PubMed ID: 29931654
[TBL] [Abstract][Full Text] [Related]
27. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
Lazaridis L; Schmidt T; Oster C; Blau T; Pierscianek D; Siveke JT; Bauer S; Schildhaus HU; Sure U; Keyvani K; Kleinschnitz C; Stuschke M; Herrmann K; Deuschl C; Scheffler B; Kebir S; Glas M
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3513-3526. PubMed ID: 35953681
[TBL] [Abstract][Full Text] [Related]
28. Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.
Muzyka L; Goff NK; Choudhary N; Koltz MT
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445633
[TBL] [Abstract][Full Text] [Related]
29. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Friedrich M; Bunse L; Wick W; Platten M
Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
32. Contemporary management of high-grade gliomas.
Sim HW; Morgan ER; Mason WP
CNS Oncol; 2018 Jan; 7(1):51-65. PubMed ID: 29241354
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Options in Neuro-Oncology.
Afonso M; Brito MA
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628161
[TBL] [Abstract][Full Text] [Related]
34. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
35. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma.
Galanis E; Wen PY; de Groot JF; Weller M
Hematol Oncol Clin North Am; 2022 Feb; 36(1):113-132. PubMed ID: 34756799
[TBL] [Abstract][Full Text] [Related]
36. Identifying predictors of glioma evolution from longitudinal sequencing.
Mu Q; Chai R; Pang B; Yang Y; Liu H; Zhao Z; Bao Z; Song D; Zhu Z; Yan M; Jiang B; Mo Z; Tang J; Sa JK; Cho HJ; Chang Y; Chan KHY; Loi DSC; Tam SST; Chan AKY; Wu AR; Liu Z; Poon WS; Ng HK; Chan DTM; Iavarone A; Nam DH; Jiang T; Wang J
Sci Transl Med; 2023 Oct; 15(716):eadh4181. PubMed ID: 37792958
[TBL] [Abstract][Full Text] [Related]
37. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
38. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
40. Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma.
Belyaev AY; Kobyakov GL; Shmakov PN; Telysheva EN; Strunina YV; Usachev DY
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(5):21-27. PubMed ID: 36252190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
